Fusion Pharmaceuticals (NASDAQ:FUSN) Lifted to Strong-Buy at Raymond James

Fusion Pharmaceuticals (NASDAQ:FUSN – Get Free Report) was upgraded by analysts at Raymond James from an “outperform” rating to a “strong-buy” rating in a research note issued on Wednesday, Marketbeat reports. The brokerage presently has a $15.00 price target on the stock, up from their previous price target of $12.00. Raymond James’ price target indicates […]

Related Keywords

United States ,Canada ,Raymond Jame ,Raymond James ,Sphera Funds Management ,News Ratings For Fusion Pharmaceuticals Daily ,Fusion Pharmaceuticals Stock Performance ,Royal Bank ,Analyst Recommendations For Fusion Pharmaceuticals ,Fusion Pharmaceuticals Inc ,Forefront Analytics ,Fusion Pharmaceuticals Company Profile ,Eagle Health Investments ,Fusion Pharmaceuticals ,Institutional Investors Weigh In On Fusion Pharmaceuticals ,Hermes Inc ,Get Free Report ,Partners Management ,Funds Management ,Pharmaceuticals Inc ,Fusion Pharmaceuticals Daily ,Nasdaq Fusn ,Fusn ,Medical ,Upgrade ,